ULTRACAINE D-S INJECTION SOLUTION

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

EPINEPHRINE; ARTICAINE HYDROCHLORIDE

Beschikbaar vanaf:

HANSAMED LIMITED

ATC-code:

N01BB58

INN (Algemene Internationale Benaming):

ARTICAINE, COMBINATIONS

Dosering:

5MCG; 40MG

farmaceutische vorm:

SOLUTION

Samenstelling:

EPINEPHRINE 5MCG; ARTICAINE HYDROCHLORIDE 40MG

Toedieningsweg:

BLOCK/INFILTRATION

Eenheden in pakket:

1.7ML

Prescription-type:

Ethical

Therapeutisch gebied:

LOCAL ANESTHETICS

Product samenvatting:

Active ingredient group (AIG) number: 0226661002; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

2000-08-02

Productkenmerken

PRODUCT MONOGRAPH
ULTRACAINE D-S INJECTION _ _
(4% articaine hydrochloride with epinephrine 1:200,000 as epinephrine
hydrochloride)
ULTRACAINE D-S FORTE INJECTION_ _
(4% articaine hydrochloride with epinephrine 1:100,000 as epinephrine
hydrochloride)
Solutions for Injection_ _
Local Anesthetic for Dental Use
Date of Preparation
July 19, 2000
Manufactured by:
Sanofi - Aventis Deutschland GmbH
DATE OF REVISION:
Frankfurt am Main, Hessen, Germany
JANUARY 27, 2014
Imported by:
HANSAmed Limited
2830 Argentia Road, Unit 5 - 8
Mississauga, Ontario L5N 8G4
Submission Control No. 162166
“
ULTRACAINE
” is the registered trademark of Sanofi-Aventis Deutschland GmbH.
_Ultracaine D-S, Ultracaine D-S Forte (articaine + epinephrine
solution for injection) _
_Hansamed Ltd _
_Page 2 of 20 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...........................................................................
3
SUMMARY PRODUCT INFORMATION
...........................................................................................
3
INDICATIONS AND CLINICAL USE
.................................................................................................
3
CONTRAINDICATIONS
....................................................................................................................
3
WARNINGS AND PRECAUTIONS
...................................................................................................
4
ADVERSE REACTIONS
....................................................................................................................
6
DRUG INTERACTIONS
....................................................................................................................
7
DOSAGE AND ADMINISTRATION
...................................................................................................
7
OVERDOSAGE
.................................................................................................................................
8
ACTION AND CLINICAL PHARMACOLOGY
..........................